The ovary: cysts, screening, and tamoxifen

Autor: Mje Mourits, Agj van der Zee, Phb Willemse, Ege de Vries

Publikováno v: LANCET, 355(9220), 2078-2079. ELSEVIER SCIENCE INC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e149d239c247aebac771ebec37c98ab9
https://research.rug.nl/en/publications/2381c8fd-e2b1-466b-a5ea-99276843477c

ISOCHROMOSOME-18Q IN A GIRL WITH HOLOPROSENCEPHALY, DIGEORGE ANOMALY, AND STREAK OVARIES

Autor: Jham Tuerlings, Mje Mourits, B Leegte, Cjf Schoots, Ra Vanlingen, Aj Vanessen

Publikováno v: American Journal of Medical Genetics, 47(1), 85-88. WILEY-LISS

We report on the clinical and pathologic findings in a girl with isochromosome 18q (46, XX,i(18q)) who had combined manifestations of monosomy 18p and trisomy 18q. Major congenital anomalies included premaxillary agenesis, alobar holoprosenphaly, dou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c25683a546c6b530b0b00dc07266695
https://research.rug.nl/en/publications/3559f8c5-e634-4005-8e3a-1475cb5f974f

Reply

Autor: Phb Willemse, Ege de Vries, Agj van der Zee, Harry Hollema, Mje Mourits

Publikováno v: Human Pathology. 34:411

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dffcd446c028fff419177a7e56d9377d
https://doi.org/10.1053/hupa.2003.39

Optimizing the detection of hereditary predisposition in women with epithelial ovarian cancer: nationwide implementation of the Tumor-First workflow.

Autor: Witjes VM; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.; Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Hermkens DMA; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands., Swillens JEM; Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.; IQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands., Smolders YHCM; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands., Mourits MJE; Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Ausems MGEM; Division Laboratories, Pharmacy and Biomedical Genetics, Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands., de Hullu JA; Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands., Ligtenberg MJL; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.; Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands., Hoogerbrugge N; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands. Nicoline.Hoogerbrugge@radboudumc.nl.; Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands. Nicoline.Hoogerbrugge@radboudumc.nl.

Publikováno v: Familial cancer [Fam Cancer] 2024 Nov; Vol. 23 (4), pp. 429-436. Date of Electronic Publication: 2024 May 29.

Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers.

Autor: Stroot IAS; University of Groningen, University Medical Center Groningen, Department of Gynecologic Oncology, Groningen, the Netherlands; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, the Netherlands. Electronic address: i.a.s.stroot@umcg.nl., Bart J; University of Groningen, University Medical Center Groningen, Department of Pathology, Groningen, the Netherlands., Hollema H; University of Groningen, University Medical Center Groningen, Department of Pathology, Groningen, the Netherlands., Jalving M; University of Groningen, University Medical Center Groningen, Department of Medical Oncology, Groningen, the Netherlands., Wagner MM; University of Groningen, University Medical Center Groningen, Department of Gynecologic Oncology, Groningen, the Netherlands., Yigit R; University of Groningen, University Medical Center Groningen, Department of Gynecologic Oncology, Groningen, the Netherlands., van Doorn HC; Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Gynecologic Oncology, Rotterdam, the Netherlands., de Hullu JA; Radboud University Medical Center, Department of Obstetrics and Gynecology, Nijmegen, the Netherlands., Gaarenstroom KN; Leiden University Medical Center, Department of Obstetrics and Gynecology, Leiden, the Netherlands., van Beurden M; Antoni van Leeuwenhoek, Department of Gynecology, Amsterdam, the Netherlands., van Lonkhuijzen LRCW; Amsterdam University Medical Center-Center for Gynecological Oncology Amsterdam, Department of Gynecologic Oncology, Amsterdam, the Netherlands., Slangen BFM; Maastricht University Medical Center, Department of Gynecology, Maastricht, the Netherlands., Zweemer RP; University Medical Center Utrecht, Department of Gynecologic Oncology, Utrecht, the Netherlands., Gómez García EB; University Medical Center Maastricht, Department of Clinical Genetics, Maastricht, the Netherlands., Ausems MGEM; University Medical Center Utrecht, Department of Genetics, Division Laboratories, Pharmacy and Biomedical Genetics, Utrecht, the Netherlands., Boere IA; Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Medical Oncology, Rotterdam, the Netherlands., van Hest LP; Amsterdam UMC, Location Vrije Universiteit Amsterdam, Department of Human Genetics, Amsterdam, the Netherlands., Duijkers FAM; Amsterdam UMC, University of Amsterdam, Department of Human Genetics, Amsterdam, the Netherlands., van Asperen CJ; Leiden University Medical Center, Department of Human Genetics & Department of Pathology, Leiden, the Netherlands., Schmidt MK; Leiden University Medical Center, Department of Human Genetics & Department of Pathology, Leiden, the Netherlands; Netherlands Cancer Institute, Department of Epidemiology, Amsterdam, the Netherlands; Netherlands Cancer Institute, Division of Molecular Pathology, Amsterdam, the Netherlands., Wevers MR; Radboud University Medical Center, Department of Clinical Genetics, Nijmegen, the Netherlands., Ruijs MWG; Netherlands Cancer Institute, Department of Clinical Genetics, Amsterdam, the Netherlands., Devilee P; Leiden University Medical Center, Department of Human Genetics & Department of Pathology, Leiden, the Netherlands., Collée JM; Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Clinical Genetics, Rotterdam, the Netherlands., Hebon Investigators; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Coordinating Center: Netherlands Cancer Institute, Amsterdam, the Netherlands., de Bock GH; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, the Netherlands., Mourits MJE; University of Groningen, University Medical Center Groningen, Department of Gynecologic Oncology, Groningen, the Netherlands.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2024 Aug; Vol. 187, pp. 198-203. Date of Electronic Publication: 2024 May 24.